rhodamine 123 has been researched along with 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrieux, J; Formstecher, P; Jouy, N; Kuranda, K; Le Roy, H; Masselot, B; Mortier, L; Polakowska, R; Prochazkova, J; Quesnel, B; Ségard, P; Touil, Y; Vandomme, J; Wolowczuk, I; Zuliani, T | 1 |
1 other study(ies) available for rhodamine 123 and 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one
| Article | Year |
|---|---|
The PI3K/AKT signaling pathway controls the quiescence of the low-Rhodamine123-retention cell compartment enriched for melanoma stem cell activity.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Cycle; Cell Line, Tumor; Chromones; Cyclin D1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Melanoma; Morpholines; Neoplastic Stem Cells; Octamer Transcription Factor-3; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Signal Transduction; Tumor Cells, Cultured | 2013 |